Revision as of 13:50, 14 October 2017

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

6 regimens on this page 7 variants on this page

If you're looking for squamous cell carcinoma (SCC) regimens, they've been moved to a separate page.

Guidelines

NCCN

NCCN Guidelines - Basal Cell Skin Cancer

Neoadjuvant chemotherapy

Bleomycin & Cisplatin

back to top

Regimen

Study	Evidence
Denic et al. 1999	Pilot, <20 patients reported

Case reports only.

Chemotherapy

Cisplatin (Platinol) 20 mg/m² IV once per day on days 1 to 4
Bleomycin (Blenoxane) 20 mg IV once per day on days 1 to 4

21-day cycle for 3 cycles

References

Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol. 1999 Feb;22(1):32-4. link to original article contains protocol PubMed

Advanced disease, all lines of therapy

Cisplatin & Doxorubicin

back to top

Regimen

Study	Evidence
Guthrie et al. 1990	Non-randomized

Chemotherapy

Cisplatin (Platinol) 75 mg/m² IV once on day 1
Doxorubicin (Adriamycin) 50 mg/m² IV once on day 1

21-day cycles

References

Guthrie TH, Porubsky ES. Successful systemic chemotherapy of advanced squamous and basal cell carcinoma of the skin with cis-diamminedichloroplatinum III and doxorubicin. Laryngoscope. 1982 Nov;92(11):1298-9. PubMed
Guthrie TH Jr, McElveen LJ, Porubsky ES, Harmon JD. Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer. 1985 Apr 15;55(8):1629-32. PubMed
Guthrie TH Jr, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990 Feb;8(2):342-6. link to original article contains verified protocol PubMed

Cisplatin & Paclitaxel

back to top

Regimen

Study	Evidence
Jefford et al. 2004	Pilot, <20 patients reported

Case report only.

Chemotherapy

Cisplatin (Platinol) 75 mg/m² IV once on day 1
Paclitaxel (Taxol) 135 mg/m² IV over 3 hours once on day 1

21-day cycles

References

Jefford M, Kiffer JD, Somers G, Daniel FJ, Davis ID. Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel. ANZ J Surg. 2004 Aug;74(8):704-5. link to original article contains verified protocol PubMed

Sonidegib monotherapy

back to top

Regimen

Study	Evidence	Comparator
Migden et al. 2015 (BOLT)	Randomized Phase II	Sonidegib 800 mg

In BOLT, 200 mg was assessed as having a better benefit-to-risk profile than the other tested dose, 800 mg.

Chemotherapy

Sonidegib (Odomzo) 200 mg PO once per day

Given until progression of disease or unacceptable toxicity

References

Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kudchadkar R, Trefzer U, Gogov S, Pallaud C, Yi T, Mone M, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Chang AL, Cornélis F, Lear JT, Sellami D, Dummer R. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015 Jun;16(6):716-28. link to original article contains verified protocol PubMed

Vismodegib monotherapy

back to top

Regimen

Study	Evidence
Sekulic et al. 2012	Non-randomized

Chemotherapy

Vismodegib (Erivedge) 150 mg PO once per day

References

Phase I: Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC Jr, de Sauvage FJ, Low JA. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009 Sep 17;361(12):1164-72. Epub 2009 Sep 2. link to original article contains verified protocol PubMed
Phase I: LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von Hoff DD. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011 Apr 15;17(8):2502-11. Epub 2011 Feb 7. link to original article contains verified protocol link to PMC article PubMed
Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012 Jun 7;366(23):2171-9. link to original article link to PMC article PubMed

@@ Line 9: / Line 9: @@
 |}
 {{TOC limit|limit=3}}
+''If you're looking for [[squamous cell carcinoma (SCC)]] regimens, they've been moved to a separate page.''
 =Guidelines=
 ==NCCN==
 *[https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf NCCN Guidelines - Basal Cell Skin Cancer]
-=Basal cell carcinoma=
+=Neoadjuvant chemotherapy=
 ==Bleomycin & Cisplatin {{#subobject:3ba784|Regimen=1}}==
 {| class="wikitable" style="float:right; margin-left: 5px;"
@@ Line 29: / Line 29: @@
 |-
 |}
-''Neoadjuvant case reports only.''
+''Case reports only.''
 ====Chemotherapy====
 *[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV once per day on days 1 to 4
@@ Line 38: / Line 38: @@
 ===References===
 # Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol. 1999 Feb;22(1):32-4. [http://journals.lww.com/amjclinicaloncology/pages/articleviewer.aspx?year=1999&issue=02000&article=00008&type=abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10025376 PubMed]
+=Advanced disease, all lines of therapy=
 ==Cisplatin & Doxorubicin {{#subobject:1ab6f6|Regimen=1}}==
@@ Line 135: / Line 137: @@
 # Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012 Jun 7;366(23):2171-9. [http://www.nejm.org/doi/full/10.1056/NEJMoa1113713 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278761/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22670903 PubMed]
-=Squamous cell carcinoma=
+[[Category:Basal cell carcinoma (BCC) regimens]]
-==Bleomycin & Cisplatin {{#subobject:25eb19|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
-|-
-|[[#top|back to top]]
-|}
-===Regimen {{#subobject:d4d7f3|Variant=1}}===
-{| border="1" style="text-align:center;" !align="left"
-|'''Study'''
-|[[Levels_of_Evidence#Evidence|'''Evidence''']]
-|-
-|[http://journals.lww.com/amjclinicaloncology/pages/articleviewer.aspx?year=1999&issue=02000&article=00008&type=abstract Denic et al. 1999]
-|style="background-color:#FF0000"|Pilot, <20 patients reported
-|-
-|}
-''Neoadjuvant case reports only.''
-====Chemotherapy====
-*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV once per day on days 1 to 4
-*[[Bleomycin (Blenoxane)]] 20 mg IV once per day on days 1 to 4
-'''21-day cycle for 3 cycles'''
-===References===
-# Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol. 1999 Feb;22(1):32-4. [http://journals.lww.com/amjclinicaloncology/pages/articleviewer.aspx?year=1999&issue=02000&article=00008&type=abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10025376 PubMed]
-==Cetuximab monotherapy {{#subobject:5f3411|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
-|-
-|[[#top|back to top]]
-|}
-===Regimen #1 {{#subobject:f75d12|Variant=1}}===
-{| border="1" style="text-align:center;" !align="left"
-|'''Study'''
-|[[Levels_of_Evidence#Evidence|'''Evidence''']]
-|-
-|[http://jco.ascopubs.org/content/29/25/3419.long Maubec et al. 2011]
-|style="background-color:#EEEE00"|Phase II
-|-
-|}
-====Chemotherapy====
-*[[Cetuximab (Erbitux)]] 400 mg/m<sup>2</sup> IV once, then 250 mg/m<sup>2</sup> IV once per week
-'''Given for at least 6 weeks, to be continued until progression of disease or unacceptable toxicity'''
-===Regimen #2 {{#subobject:7579ab|Variant=1}}===
-{| border="1" style="text-align:center;" !align="left"
-|'''Study'''
-|[[Levels_of_Evidence#Evidence|'''Evidence''']]
-|-
-|[http://onlinelibrary.wiley.com/doi/10.1002/hed.21299/abstract Kim et al. 2011]
-|style="background-color:#FF0000"|Pilot, <20 patients reported
-|-
-|}
-''Case report only.''
-====Chemotherapy====
-*[[Cetuximab (Erbitux)]] 400 mg/m<sup>2</sup> IV once, then 250 mg/m<sup>2</sup> IV once per week
-'''3 month course'''
-===Regimen #3 {{#subobject:608448|Variant=1}}===
-{| border="1" style="text-align:center;" !align="left"
-|'''Study'''
-|[[Levels_of_Evidence#Evidence|'''Evidence''']]
-|-
-|[http://onlinelibrary.wiley.com/doi/10.1111/j.1524-4725.2010.01786.x/abstract Miller et al. 2010]
-|style="background-color:#FF0000"|Pilot, <20 patients reported
-|-
-|}
-''Case report only.''
-====Chemotherapy====
-*[[Cetuximab (Erbitux)]] 400 mg/m<sup>2</sup> IV once on day 1, then 250 mg/m<sup>2</sup> IV once per day on days 8, 15, 22
-'''6-month cycles, given indefinitely unless progression occurs'''
-===References===
-# Bauman JE, Eaton KD, Martins RG. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol. 2007 Jul;143(7):889-92. [http://archderm.ama-assn.org/cgi/content/full/143/7/889 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17638733 PubMed]
-# Suen JK, Bressler L, Shord SS, Warso M, Villano JL. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anticancer Drugs. 2007 Aug;18(7):827-9. [http://journals.lww.com/anti-cancerdrugs/pages/articleviewer.aspx?year=2007&issue=08000&article=00011&type=abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17581306 PubMed]
-# Arnold AW, Bruckner-Tuderman L, Zuger C, Itin PH. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. Dermatology. 2009;219(1):80-3. Epub 2009 May 13. [http://content.karger.com/produktedb/produkte.asp?DOI=10.1159/000218714 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19439919 PubMed]
-# Miller K, Sherman W, Ratner D. Complete clinical response to cetuximab in a patient with metastatic cutaneous squamous cell carcinoma. Dermatol Surg. 2010 Dec;36(12):2069-74. Epub 2010 Oct 11. [http://onlinelibrary.wiley.com/doi/10.1111/j.1524-4725.2010.01786.x/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21044226 PubMed] content property of [http://hemonc.org HemOnc.org]
-# Kim S, Eleff M, Nicolaou N. Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck. Head Neck. 2011 Feb;33(2):286-8. [http://onlinelibrary.wiley.com/doi/10.1002/hed.21299/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19953623 PubMed]
-# Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, Certain A, Duval X, Crickx B, Buffard V, Basset-Seguin N, Saez P, Duval-Modeste AB, Adamski H, Mansard S, Grange F, Dompmartin A, Faivre S, Mentré F, Avril MF. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011 Sep 1;29(25):3419-26. Epub 2011 Aug 1. [http://jco.ascopubs.org/content/29/25/3419.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21810686 PubMed]
-==Cisplatin & Doxorubicin {{#subobject:ab12b5|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
-|-
-|[[#top|back to top]]
-|}
-===Regimen {{#subobject:f6ac66|Variant=1}}===
-{| border="1" style="text-align:center;" !align="left"
-|'''Study'''
-|[[Levels_of_Evidence#Evidence|'''Evidence''']]
-|-
-|[http://jco.ascopubs.org/content/8/2/342.long Guthrie et al. 1990]
-|style="background-color:#EEEE00"|Non-randomized
-|-
-|}
-====Chemotherapy====
-*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
-*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
-'''21-day cycles'''
-===References===
-# Guthrie TH, Porubsky ES. Successful systemic chemotherapy of advanced squamous and basal cell carcinoma of the skin with cis-diamminedichloroplatinum III and doxorubicin. Laryngoscope. 1982 Nov;92(11):1298-9. [https://www.ncbi.nlm.nih.gov/pubmed/6890609 PubMed]
-# Guthrie TH Jr, McElveen LJ, Porubsky ES, Harmon JD. Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer. 1985 Apr 15;55(8):1629-32. [https://www.ncbi.nlm.nih.gov/pubmed/4038911 PubMed]
-# Guthrie TH Jr, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990 Feb;8(2):342-6. [http://jco.ascopubs.org/content/8/2/342.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2405109 PubMed]
-==Cisplatin, Interferon alfa-2a, Isotretinoin {{#subobject:74bf3|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
-|-
-|[[#top|back to top]]
-|}
-===Regimen {{#subobject:399afe|Variant=1}}===
-{| border="1" style="text-align:center;" !align="left"
-|'''Study'''
-|[[Levels_of_Evidence#Evidence|'''Evidence''']]
-|-
-|[http://jco.ascopubs.org/content/20/2/364.long Shin et al. 2002]
-|style="background-color:#EEEE00"|Phase II
-|-
-|}
-''Note: Shin et al. 2002 did not clearly specify whether the interferon alfa used in the trial was 2a or 2b, but based on the details in the paper and the references cited, it is inferred that interferon alfa-2a was used.''
-====Chemoimmunotherapy====
-*[[Interferon alfa-2a (Roferon-A)]] 5,000,000 units/m<sup>2</sup> SC 3 times per week
-*[[Isotretinoin (Accutane)]] 1 mg/kg PO once per day
-*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV once per week
-===References===
-# Shin DM, Glisson BS, Khuri FR, Clifford JL, Clayman G, Benner SE, Forastiere AA, Ginsberg L, Liu D, Lee JJ, Myers J, Goepfert H, Lotan R, Hong WK, Lippman SM. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol. 2002 Jan 15;20(2):364-70. [http://jco.ascopubs.org/content/20/2/364.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11786562 PubMed]
-[[Category:Skin BCC regimens]]
-[[Category:Skin SCC regimens]]
 [[Category:Disease-specific pages]]
 [[Category:Skin cancers]]

Difference between revisions of "Cutaneous basal cell carcinoma"

Revision as of 13:50, 14 October 2017

Contents

Guidelines

NCCN

Neoadjuvant chemotherapy

Bleomycin & Cisplatin

Regimen

Chemotherapy

References

Advanced disease, all lines of therapy

Cisplatin & Doxorubicin

Regimen

Chemotherapy

References

Cisplatin & Paclitaxel

Regimen

Chemotherapy

References

Sonidegib monotherapy

Regimen

Chemotherapy

References

Vismodegib monotherapy

Regimen

Chemotherapy

References

Navigation menu

Search